drugset
drugset / Trial / NCT00738387

A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer

NCT00738387 ↗

Phase 3 Terminated 900 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to determine if adding ASA404 to docetaxel chemotherapy makes the cancer treatment more effective in patients with locally advanced or metastatic non-small cell lung cancer

Timeline

Start
2008-12
Primary completion
2010-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject ASA404 Unknown 1800 mg/m2 Intravenous
Background Docetaxel Small molecule 75 mg/m2 Intravenous

Indications

non-small cell lung carcinoma